Lab
Specialty Drug Testing, LLC
Specialty Drug Testing, LLC was paid $3.59M by Medicaid between Jan 2018 and Feb 2022, across 139 billing codes. Its largest line is 81408, — 16% of everything it billed.
33Billing provider infoSPECIALTY DRUG TESTING, LLC
MONROE, LA 71203
MONROE, LA 71203
33aNPI1639577091assigned 12/16/2014
33bProvider typeClinical Medical Laboratory
28Total paid$3.59M
24GClaims83,781
24DCodes billed139
24AFirst – last monthJan 2018 – Feb 2022
Compared with peers
Next to other Clinical Medical Laboratory providers in Louisiana
Rank by total paid#15 of 66
Median peer was paid$253K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,588 | $414K | |
| 2019 | 46,777 | $2.79M | |
| 2020 | 8,693 | $288K | |
| 2021 | 2,840 | $70K | |
| 2022 | 883 | $21K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81408 | 16% | 1,159 | 680 | $586K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.7% | 4,523 | 3,735 | $311K |
| 81298 | 7.3% | 901 | 695 | $263K | |
| 81292 | 5.5% | 835 | 653 | $196K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 5.1% | 2,880 | 1,813 | $182K |
| 81404 | 4.8% | 1,682 | 805 | $171K | |
| 81317 | 4.7% | 1,077 | 829 | $168K | |
| 81201 | 4.6% | 893 | 687 | $164K | |
| 81406 | 4.5% | 1,456 | 678 | $160K | |
| 81295 | 4.4% | 902 | 695 | $156K | |
| 81405 | 4.3% | 1,259 | 817 | $153K | |
| 81321 | 3.6% | 830 | 649 | $130K |
127 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.2% | 2,729 | $114K |
| 81259 | 2.7% | 419 | $96K | |
| 81323 | 2.1% | 482 | $76K | |
| 81203 | 1.4% | 481 | $51K | |
| 80050 | General health panel | 1.1% | 1,483 | $40K |
| 81319 | 1.0% | 485 | $37K | |
| 81242 | <1% | 683 | $32K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 35 | $30K |
| 81300 | <1% | 483 | $30K | |
| 81294 | <1% | 304 | $24K | |
| 81334 | <1% | 169 | $22K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,903 | $22K |
| 81297 | <1% | 303 | $21K | |
| 81162 | <1% | 754 | $21K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,381 | $21K |
| 81236 | <1% | 169 | $20K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,699 | $20K |
| 81325 | <1% | 415 | $19K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,105 | $16K |
| 80061 | Lipid panel | <1% | 2,280 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,275 | $13K |
| 82607 | <1% | 904 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,681 | $7K |
| 84439 | <1% | 1,062 | $6K | |
| 80323 | <1% | 741 | $5K | |
| 82746 | <1% | 573 | $5K | |
| 80346 | <1% | 836 | $5K | |
| 80370 | <1% | 676 | $4K | |
| 80335 | <1% | 274 | $4K | |
| 80372 | <1% | 726 | $4K | |
| 80373 | <1% | 679 | $4K | |
| 80349 | <1% | 814 | $4K | |
| 80348 | <1% | 868 | $4K | |
| 80368 | <1% | 672 | $4K | |
| 80361 | <1% | 837 | $4K | |
| 80365 | <1% | 859 | $4K | |
| 84403 | <1% | 253 | $4K | |
| 80338 | <1% | 689 | $4K | |
| 81211 | <1% | 147 | $4K | |
| 80342 | <1% | 285 | $4K | |
| 80358 | <1% | 800 | $4K | |
| 80367 | <1% | 229 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 241 | $3K |
| 80353 | <1% | 792 | $3K | |
| 80359 | <1% | 806 | $3K | |
| 82670 | <1% | 214 | $3K | |
| 80329 | <1% | 280 | $3K | |
| 80325 | <1% | 369 | $3K | |
| 83992 | <1% | 527 | $3K | |
| 80332 | <1% | 220 | $3K | |
| 80074 | <1% | 126 | $3K | |
| 83735 | <1% | 719 | $3K | |
| 82728 | <1% | 451 | $3K | |
| 84480 | <1% | 608 | $3K | |
| 80363 | <1% | 290 | $3K | |
| 80356 | <1% | 683 | $3K | |
| 80354 | <1% | 732 | $3K | |
| 84270 | <1% | 210 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,497 | $3K |
| 80360 | <1% | 676 | $3K | |
| 82977 | <1% | 581 | $2K | |
| 81225 | <1% | 18 | $2K | |
| 84146 | <1% | 207 | $2K | |
| 83002 | <1% | 209 | $2K | |
| 83001 | <1% | 208 | $2K | |
| 84100 | <1% | 651 | $2K | |
| 83615 | <1% | 500 | $2K | |
| 86376 | <1% | 227 | $2K | |
| 86800 | <1% | 191 | $2K | |
| 84481 | <1% | 248 | $2K | |
| 84144 | <1% | 159 | $2K | |
| 84436 | <1% | 664 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 43 | $1K |
| 81003 | <1% | 801 | $1K | |
| 84153 | <1% | 114 | $1K | |
| 82248 | <1% | 453 | $1K | |
| 83540 | <1% | 418 | $1K | |
| 86803 | <1% | 114 | $1K | |
| 81401 | <1% | 38 | $1K | |
| 84479 | <1% | 542 | $1K | |
| 83550 | <1% | 226 | $1K | |
| 83090 | <1% | 122 | $975.16 | |
| 83690 | <1% | 250 | $885.39 | |
| 84681 | <1% | 100 | $850.26 | |
| 82627 | <1% | 91 | $845.52 | |
| 82533 | <1% | 106 | $843.65 | |
| 82150 | <1% | 249 | $830.05 | |
| 81400 | <1% | 18 | $767.50 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 170 | $743.65 |
| 81355 | <1% | 18 | $720.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 224 | $692.05 |
| 81001 | <1% | 326 | $685.94 | |
| 86141 | <1% | 72 | $581.44 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 65 | $566.31 |
| 84702 | <1% | 110 | $565.59 | |
| 85652 | <1% | 448 | $545.15 | |
| 86769 | <1% | 17 | $522.73 | |
| 87088 | <1% | 117 | $522.18 | |
| 83525 | <1% | 95 | $477.46 | |
| 81403 | <1% | 89 | $467.16 | |
| 81291 | <1% | 18 | $400.00 | |
| 81241 | <1% | 18 | $400.00 | |
| 81240 | <1% | 18 | $400.00 | |
| 81226 | <1% | 18 | $400.00 | |
| 81227 | <1% | 18 | $400.00 | |
| 82550 | <1% | 99 | $291.05 | |
| 80375 | <1% | 448 | $266.79 | |
| 80324 | <1% | 461 | $259.74 | |
| 84550 | <1% | 128 | $237.84 | |
| 80355 | <1% | 416 | $234.47 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 34 | $216.41 |
| 80320 | <1% | 24 | $185.04 | |
| 80336 | <1% | 404 | $156.63 | |
| 80362 | <1% | 435 | $151.58 | |
| 80371 | <1% | 386 | $132.78 | |
| 80357 | <1% | 404 | $129.00 | |
| 80366 | <1% | 404 | $125.50 | |
| 86140 | <1% | 113 | $125.01 | |
| 85004 | <1% | 278 | $98.06 | |
| 85048 | <1% | 278 | $38.10 | |
| 81436 | <1% | 167 | $34.06 | |
| 81435 | <1% | 166 | $34.06 | |
| 82947 | <1% | 21 | $25.66 | |
| 85008 | <1% | 38 | $3.43 | |
| 82172 | 0% | 180 | $0.00 | |
| 81015 | 0% | 13 | $0.00 | |
| 81288 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLUITT, SUSAN (OWNER/OPERATOR)
| Provider | Location | Paid |
|---|---|---|
| Black Water Lab LLC | Monroe, LA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.